O Keefe Stevens Advisory Inc. Increases Stake in Pfizer Inc. by 47.8%

O Keefe Stevens Advisory Inc. has recently reported a significant increase in its holdings of Pfizer Inc. (NYSE:PFE). According to the latest Form 13F filing with the Securities & Exchange Commission, the fund raised its stake by 47.8% during the fourth quarter. The advisory firm now owns a total of 95,878 shares of the biopharmaceutical company's stock, having acquired an additional 31,010 shares.

Pfizer is now a notable part of O Keefe Stevens Advisory Inc.'s investment portfolio, accounting for 0.8% of its total holdings. The total value of the shares owned by the fund in Pfizer was reported to be $2,544,000 in the most recent filing.

Changes in Institutional Holdings

Other institutional investors have also adjusted their stakes in Pfizer recently. For instance, WCG Wealth Advisors LLC increased its position by 15.3% in the second quarter, now owning 32,347 shares valued at $905,000 after acquiring 4,295 additional shares. Similarly, XTX Topco Ltd boosted its Pfizer stake significantly by 206.9%, now holding 73,946 shares worth $2,069,000 after purchasing 49,851 shares.

ProVise Management Group LLC and Cowa LLC also made changes, with ProVise increasing its shares by 1.7% to own 128,926 shares valued at $3,607,000, and Cowa acquiring a new position in Pfizer worth about $232,000 during the same period. Intech Investment Management LLC saw a 30.3% growth in its holdings, now owning 725,663 shares valued at $20,304,000. Overall, institutional investors collectively hold 68.36% of Pfizer’s stock.

Current Stock Performance

As of the latest trading session, Pfizer's stock opened at $26.30. The company has a quick ratio of 0.73, a current ratio of 1.00, and a debt-to-equity ratio of 0.63. Over the past year, Pfizer’s stock has fluctuated between a low of $24.48 and a high of $31.54, giving it a market capitalization of $149.06 billion, and a price-to-earnings ratio of 35.55. The stock also has a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Recent Earnings Report

On October 29, Pfizer announced its latest earnings results, reporting earnings of $1.06 per share, significantly surpassing analysts' expectations of $0.64. The company's quarterly revenue was reported at $17.70 billion, exceeding the consensus estimate of $14.92 billion. Year-over-year, Pfizer's revenue increased by 31.2%, contrasting with a loss of ($0.17) EPS during the same quarter the previous year. Analysts predict an EPS of 2.94 for Pfizer in the current year.

Dividend Increase

Pfizer also declared a quarterly dividend of $0.43, which is scheduled to be paid on March 7. Stockholders as of record on January 24 will receive this dividend, which equates to an annualized dividend of $1.72, yielding 6.54%. This marks an increase from the previous quarterly dividend of $0.42, while the company's dividend payout ratio stands at 227.03%.

Analyst Ratings

Pfizer has attracted attention from analysts, with Guggenheim lowering its target price from $35.00 to $33.00, maintaining a "buy" rating. Cantor Fitzgerald reaffirmed an "overweight" rating with a price target of $45.00. Meanwhile, Sanford C. Bernstein initiated coverage with a "market perform" rating at a $32.00 target price. StockNews.com has adjusted its rating from "strong-buy" to "buy." Presently, one analyst has issued a sell rating, eight have hold ratings, six a buy rating, and two a strong buy rating on the stock. The consensus rating reflects a "Moderate Buy" with an average price target of $32.00.

Insider Activity

In related news, Director Scott Gottlieb acquired 1,000 shares on October 30 at an average price of $28.24 per share, totaling $28,240. Following this transaction, he now holds 10,000 shares valued at approximately $282,400, indicating an 11.11% increase in his ownership. This transaction was officially reported to the Securities & Exchange Commission.

About Pfizer Inc.

Pfizer Inc. is engaged in the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products across various markets, including the United States and Europe. They offer medicines and vaccines in several therapeutic areas, including cardiovascular, infectious diseases, and COVID-19 treatments.

Pfizer, Investments, Dividends